Page 4 of Research

The FDA’s review of TissuGlu included data from a clinical study of 130 participants undergoing elective abdominoplasty

Cosentyx approval is based on phase III programme demonstrating high, sustained efficacy in the skin clearance of moderate-to-severe plaque psoriasis

Dr T Rajkumar, Director and Scientific Director, Cancer Institute (WIA), Adyar elaborates about the ongoing research work at the institute…

CLEAR is the second head-to-head study for Cosentyx following the phase III Fixture study that showed Cosentyx was superior to…

A 35 per cent increased risk of type II diabetes was found in those with group B

The government is doing many positive things in the biosciences, but could do more, in terms of how it sees…

The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011

(ODAC) did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated multiple myeloma when used…

The FDA Medicare analysis is based on patient data from elderly patients enrolled in Medicare

Patients with psoriatic arthritis were 36 per cent more likely than the comparison group to suffer a heart attack

DIBER has transferred the technology of the drug, which is being showcased at the ongoing Arogya Expo 2014

The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhoea

To enroll patients in the imminent HEP002 Phase IIb/ III clinical trial

Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection

Akynzeo treats nausea and vomiting in patients undergoing cancer chemotherapy